Zymergen Acquires Lodo Therapeutics
May 28, 2021
Zymergen Inc. acquired Lodo Therapeutics Corporation from Accelerator Life Science Partners (ALSP), integrating Lodo’s metagenomic natural‑product discovery platform into Zymergen’s technology stack. ALSP had been an investor and operator of Lodo following a $17 million Series A and a collaboration with Genentech; the financial terms of the deal were not disclosed by ALSP in its announcement.
- Buyers
- Zymergen Inc.
- Targets
- Lodo Therapeutics Corporation
- Sellers
- Accelerator Life Science Partners I (ALSP I)
- Industry
- Biotechnology
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.